A South Korean biotech company is likely to benefit greatly from the policy of the U.S. Food and Drug Administration, which ...

With one of the most densely concentrated life sciences hubs in Europe, the Netherlands sets its sights on becoming a global ...

Gyre Therapeutics ("Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 ...

Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have expanded since the acquisition, doubling employees to 100 and planning to ...

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

Good morning. Biotech was not faring well yesterday, after we got the news that Vinay Prasad was chosen to be the next ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year ...

A federal judge ruled two weeks ago that parts of its lucrative digital ad network have been improperly abusing its market ...

Investors reacted negatively to the news. The company’s stock fell more than 16% yesterday. It’s also a setback in ...

The ASX has opened higher despite renewed talk of tariffs in the US, which drove global markets lower in overnight trading.

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...